The problem with cleaning up industrial contamination is that the best tools are often the most brutal. Excavation, incineration, and chemical treatments can be effective, but they are also expensive, energy-intensive, and tend to leave a site looking like a battlefield. Katherine French, an environmental scientist with a doctorate from Oxford, thought there must be a more elegant solution. She founded BluumBio in 2021 on the premise that the best clean-up crew already exists in nature [bluumbio.com, Unknown].
The company’s bet is that engineered microbes and plants can be deployed to degrade pollutants where they lie, turning a toxic liability into, ideally, harmless byproducts like water and carbon dioxide. It’s a concept with deep academic roots, but one that has struggled to find a reliable commercial formula. BluumBio is trying to build that formula, one proprietary bacterial blend at a time.
The biological wedge
BluumBio’s platform spans organism discovery, enzyme optimization, and product development [LinkedIn, Unknown]. The commercial output is a growing catalog of targeted, shelf-stable microbial products. Each is designed for a specific class of contaminant that plagues industries from mining to manufacturing.
- Bluum Helios targets petroleum hydrocarbons.
- Bluum Delta is formulated for PFAS, the notorious “forever chemicals.”
- Bluum Firefly goes after PCBs.
- Bluum Maris aims at plastics, with suggested uses from industrial composting to microplastic removal in water treatment [bluumbio.com/store].
The model isn’t just selling jugs of bacteria. The company pairs its products with treatability studies, field trials, and deployment support, offering a “Better Customer Care” plan that includes sample kits and a dedicated support team [bluumbio.com/store]. The claim is that its products have already been used to treat real soil and water from customer sites, though the company has not publicly named those customers [watertoday.ca, Unknown].
The founder’s path from lab to field
Katherine French is a solo founder, which is uncommon in biotech. Her path to BluumBio was academic and translational. She conducted the underlying research at UC Berkeley after her DPhil at Oxford, and her background includes commercialization work at the Joint Bioenergy Institute and Berkeley National Lab [bluumbio.com, Unknown] [workatastartup.com, Unknown]. This hybrid experience,deep in the science but with an eye toward application,shapes the company.
The early team reflects a focus on the bench. Drew Hendrickson, Head of Organism Discovery, came from the Arkin Lab at Berkeley Lab [theorg.com, Retrieved 2026]. Jordan Baker is listed as Chief Technology Officer, managing research and scale-up [rocketreach.co, Retrieved 2026]. It’s a lean operation; sources conflict, but employee counts hover between four and six people from 2021 through 2026 [Y Combinator] [rocketreach.co, Retrieved 2026]. One notable, if unverified, traction signal is a claim that this small team generated $5 million in revenue in 2024 [getlatka.com, Unknown].
A patient capital stack
BluumBio has assembled funding from a mix of venture and strategic sources, though specific round sizes are undisclosed. The table below outlines the known financing events.
| Date | Event | Key Participants | Note |
|---|---|---|---|
| 2021 | Y Combinator (S21) | Y Combinator | Summer batch participation [Y Combinator]. |
| 2021 | Pre-seed Round | Plug and Play, Day One Ventures, others | Post-money valuation reported at $12 million [Plug and Play Tech Center, Jan 2026]. |
| Oct 2024 | Mining Tech Accelerator | Founders Factory, Rio Tinto | Cohort participant; accelerator backed by A$14.4 million from Rio Tinto [healthcarediscovery.ai, Oct 2024]. |
| May 2025 | Seed Round | EQT Foundation | Funding to support PFAS trials and PCB/plastics development [EQT Foundation, May 2025]. |
| Jul 2025 | Federal Grant | NIH / NIEHS | $188,466 research grant [healthcareventurecapitalfund.com, Jul 2025]. |
The backing from the EQT Foundation, the philanthropic arm of the global investment giant, and participation in the Rio Tinto-backed accelerator point to strategic interest from heavy industry. These are not purely financial bets; they are potential pathways to future customers with massive remediation liabilities.
Where biology meets the real world
The most credible risk for BluumBio isn’t scientific,it’s commercial. Biological remediation is famously context-dependent. What works in a lab flask or a pilot plot can falter in the complex, heterogeneous environment of a real-world brownfield. Success depends on local soil chemistry, temperature, and the specific cocktail of contaminants. Scaling from a successful field trial to a standardized, repeatable service that industrial procurement officers will buy is a different kind of chemistry altogether.
The company’s answer appears to be its integrated service model. By leading with treatability studies and field trials, it can de-risk the process for the customer and gather the site-specific data needed to tune its applications. The question is whether this hands-on approach can itself scale efficiently with a team that has reportedly remained in the single digits.
The incumbent in the crosshairs
BluumBio’s products, if they work as advertised, would compete most directly with traditional remediation contractors. The incumbent isn’t a tech startup; it’s the established environmental services firm that shows up with bulldozers and incinerators. The unit economics of that battle are stark. Excavating and landfilling contaminated soil can cost anywhere from $50 to $500 per cubic yard, not including transportation and long-term liability. Incineration runs even higher.
A back-of-the-envelope calculation: if a BluumBio microbial treatment costs even one-third of the excavation price and can be applied in situ, the savings on a medium-sized site dealing with thousands of cubic yards of soil could run into the millions. That’s the economic wedge. The company isn’t just selling a greener solution; it’s selling a potentially cheaper one, with the added benefit of not turning the site into a crater. To win, BluumBio doesn’t need to out-market a software platform. It needs to consistently out-economize a backhoe.
Sources
- [bluumbio.com, Unknown] STORY, Nature, restored by nature. | https://www.bluumbio.com/story-1-1
- [bluumbio.com, Unknown] BluumBio Store | https://www.bluumbio.com/store
- [LinkedIn, Unknown] BLUUMBIO | LinkedIn | https://www.linkedin.com/company/bluumbio
- [watertoday.ca, Unknown] BluumBio | https://watertoday.ca/viewarticle.asp?article=580
- [workatastartup.com, Unknown] BluumBio | https://www.workatastartup.com/companies/bluumbio
- [Y Combinator] BLUUMBIO | Y Combinator | https://www.ycombinator.com/companies/bluumbio
- [theorg.com, Retrieved 2026] Drew Hendrickson profile | https://theorg.com
- [rocketreach.co, Retrieved 2026] Jordan Baker profile | https://rocketreach.co
- [getlatka.com, Unknown] BluumBio revenue claim | https://getlatka.com/companies/bluumbio.com
- [Plug and Play Tech Center, Jan 2026] New Investment: BluumBio | https://www.plugandplaytechcenter.com/announcing-our-investment-in/new-investment-bluumbio-leveraging-bioremediation-to-degrade-cross-industry-contaminants/
- [healthcarediscovery.ai, Oct 2024] BluumBio | https://healthcarediscovery.ai/companies/bluumbio/
- [EQT Foundation, May 2025] EQT Foundation invests in BluumBio | https://eqtgroup.com/news/eqt-foundation-invests-in-bluumbio-harnessing-the-power-of-nature-to-clean-up-pollution
- [healthcareventurecapitalfund.com, Jul 2025] BluumBio | https://healthcareventurecapitalfund.com/companies/bluumbio/